1 withdrawn. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Withdrawn 1 |
Follow oral azacitidine (CC-486): new trials by email Literature Review of oral azacitidine (CC-486) trials Research Report on oral azacitidine (CC-486)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients oral azacitidine (CC-486) - Acute Myeloid Leukemia | Phase 2 | Withdrawn | Yale University | 2023-11-01 | 2023-12-26 |
Leukemia, Myeloid, Acute (1) · Pathologic Complete Response (1)
Yale University (1)
United States (1)
Lohith Gowda, MD (1) · Marcos de Lima, MD (1)
T32CA233414 (1)